MRKR News and Press, Marker Therapeutics Inc. From 05/20/25

2025-05-20 18:47:55 ET Marker Therapeutics, Inc. (MRKR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.40%. The average open to low on the day of earnings was -7.77%. The average open...

2025-05-20 18:42:55 ET Marker Therapeutics, Inc. (MRKR) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in MRKR stock price following earnings has averaged ±2.89% , with a median of 2.63%...

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase 1 APOLLO study expected later ...

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chie...

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Ch...

2025-03-31 08:47:53 ET More on Marker Therapeutics Seeking Alpha’s Quant Rating on Marker Therapeutics Historical earnings data for Marker Therapeutics Financial information for Marker Therapeutics Read the full article on Seeking Alpha For fur...

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive fundin...

Spire Global Inc. Class A (SPIR) is expected to report $-0.97 for Q4 2024 CaliberCos Inc. (CWD) is expected to report $-0.04 for Q4 2024 Progress Software Corporation (PRGS) is expected to report $0.79 for Q1 2025 Nuvve Holding Corp. (NVVE) is expected to report for quarter end 2024-1...

Vivos Inc (RDGL) is expected to report for quarter end 2024-12-31 Nickel Creek Platinum Corp (NCPCF) is expected to report for quarter end 2024-12-31 ViewBix Inc (VBIXD) is expected to report for quarter end 2024-12-31 Forte Biosciences Inc. (FBRX) is expected to report $-4.55 for Q4 ...

2025-03-05 16:30:02 ET Jefferies analyst issues BUY recommendation for MRKR on March 5, 2025 05:24PM ET. MRKR was trading at $2.049 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold recomm...